dc.creator | Miguel Luken, MJ de | es |
dc.creator | Chaves Conde, M | es |
dc.creator | Quintana, Begoña | es |
dc.creator | Menoyo, Alicia | es |
dc.creator | Tirado, Isabel | es |
dc.creator | Miguel Luken, Veronica de | es |
dc.creator | Pachón Díaz, Jerónimo | es |
dc.creator | Carnero Moya, Amancio | es |
dc.date.accessioned | 2020-05-13T09:12:42Z | |
dc.date.available | 2020-05-13T09:12:42Z | |
dc.date.issued | 2016-01-04 | |
dc.identifier.citation | Miguel Luken, M.d., Chaves Conde, M., Quintana, B., Menoyo, A., Tirado, I., Miguel Luken, V.d.,...,Carnero Moya, A. (2016). Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. Oncotarget, 7 (22), 31723-31737. | |
dc.identifier.issn | 1949-2553 | es |
dc.identifier.uri | https://hdl.handle.net/11441/96534 | |
dc.description.abstract | Current larynx preservation treatments have achieved an improvement of
laryngoesophageal dysfunction-free survival (LDS) but lead to significant toxicities
and recurrences. At present, there is no evidence to select the group of patients that
may benefit from preservation approaches instead of surgery. Therefore, laryngeal
biomarkers could facilitate pretreatment identification of patients who could respond
to chemoradiation-based therapy. In this study, we evaluated retrospectively 53
patients with larynx cancer to determine whether gH2AX phosphorylation (pH2AX)
alone or in combination with the membrane protein MAP17 (PDZK1IP1) could be used
as prognostic biomarkers. We also evaluated whether the completion of cisplatin
treatment and radiotherapy could predict survival in combination with pH2AX.
We found that the dose of cisplatin received but not the length of the radiotherapy
influenced LDS. High-pH2AX expression was associated with prolonged LDS (HR 0.26,
p = 0.02) while MAP17 correlated with overall survival (OS) (HR 0.98, p = 0.05).
High-MAP17 and high-pH2AX combined analysis showed improved LDS (with 61.35
months vs 32.2 months, p = 0.05) and OS (with 66.6 months vs 39.8 months, p =
0.01). Furthermore, the subgroup of high-pH2AX and optimal dose of cisplatin was
also associated with OS (72 months vs 38.6 months, p = 0.03) and LDS (66.9 months
vs 27 months, p = 0.017). These findings suggest that pH2AX alone or better in
combination with MAP17 may become a novel and valuable prognostic biomarker for
patients with laryngeal carcinoma treated with preservation approaches. | es |
dc.description.sponsorship | Junta de Andalucia ISCIII-Red de Biobancos RD12/0036/0017. | es |
dc.description.sponsorship | Unión Europea, Ministerio de Economía y Competitividad PI12/00137, PI15/00045, RTICC: RD12/0036/0028 | es |
dc.description.sponsorship | Junta de Andalucía CTS-6844; CTS-1848 | es |
dc.description.sponsorship | Junta de Andalucía PI-0135-2010; PI-0306-2012 | es |
dc.description.sponsorship | Instituto Carlos III (ISCIII) PIE13/0004. | es |
dc.format | application/pdf | es |
dc.format.extent | 15 | es |
dc.language.iso | eng | es |
dc.publisher | Impact Journals | es |
dc.relation.ispartof | Oncotarget, 7 (22), 31723-31737. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Laryngeal cancer | es |
dc.subject | H2AX | es |
dc.subject | Biomarker | es |
dc.subject | Laryngeal preservation | es |
dc.subject | DDR | es |
dc.subject | Pathology Section | es |
dc.title | Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Cirugía | es |
dc.identifier.doi | 10.18632/oncotarget 9172 | es |
dc.contributor.group | Universidad de Sevilla. CTS203: Estudio de las enfermedades infecciosas | es |
dc.journaltitle | Oncotarget | es |
dc.publication.volumen | 7 | es |
dc.publication.issue | 22 | es |
dc.publication.initialPage | 31723 | es |
dc.publication.endPage | 31737 | es |